1148 related articles for article (PubMed ID: 26065479)
21. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.
Hay KA; Turtle CJ
Drugs; 2017 Mar; 77(3):237-245. PubMed ID: 28110394
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
23. New development in CAR-T cell therapy.
Wang Z; Wu Z; Liu Y; Han W
J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
[TBL] [Abstract][Full Text] [Related]
24. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
25. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
26. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
27. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
28. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
29. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
30. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
Abken H
Immunotherapy; 2015; 7(5):535-44. PubMed ID: 26065478
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
32. [CAR T-cell therapy: Balance of efficacy and safety].
Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
[TBL] [Abstract][Full Text] [Related]
33. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Qin H; Cho M; Haso W; Zhang L; Tasian SK; Oo HZ; Negri GL; Lin Y; Zou J; Mallon BS; Maude S; Teachey DT; Barrett DM; Orentas RJ; Daugaard M; Sorensen PH; Grupp SA; Fry TJ
Blood; 2015 Jul; 126(5):629-39. PubMed ID: 26041741
[TBL] [Abstract][Full Text] [Related]
34. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
35. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
[TBL] [Abstract][Full Text] [Related]
36. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
37. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
38. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
39. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
40. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
